Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03143543 · ClinicalTrials.gov registry record · Phase 1

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

A Phase 1 study, sponsored by Virginia Commonwealth University.

Terminated
Registry status
Phase 1
Development phase
171
Enrollment target

NCT03143543: Clinical Trial Phase 1 study, sponsored by Virginia Commonwealth University.

NCT03143543 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 171 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (185% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03143543, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.

TERMINATED
Registry status
Phase 1
Development phase
171 participants
Enrollment target

Study Summary

The purpose of Project 2 is to execute phase I functional magnetic resonance imaging (fMRI) studies to assess the effects of lorcaserin on brain target engagement (measured by fMRI brain activation and neural connectivity) in cocaine use disorder (CocUD) subjects and/or opioid use disorder.

Primary Outcome

To determine target engagement by lorcaserin in a cocaine-Stroop and/or opioid-Stroop cue-reactivity fMRI task in cocaine use disorder (CocUD) and/or Opioid Use Disorder Subjects

Interventions

  • DRUG Group A Lorcaserin (10mg)
  • DRUG Group A2 Lorcaserin (20 mg)
  • OTHER Group B Parallel Placebo
  • OTHER Group B2 Parallel Placebo

Trial Details

FieldValue
Enrollment Target 171 participants
Start Date 2015-07
Est. Completion 2019-12-06
Phase Phase 1
Virginia Commonwealth University

558 total trials

Why NCT03143543 stopped before completion

NCT03143543 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (185% higher).

The record links to 0 conditions, and to 4 interventions - of which Group A Lorcaserin (10mg) is the first listed.

NCT03143543 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03143543 about?

NCT03143543 is a clinical study titled "Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder". The purpose of Project 2 is to execute phase I functional magnetic resonance imaging (fMRI) studies to assess the effects of lorcaserin on brain target engagement (measured by fMRI brain activation and neural connectivity) in cocaine use disorder (CocUD) subjects and/or opioid use disorder.

What is the current status of trial NCT03143543?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2015-07. Estimated completion is 2019-12-06.

What interventions are being tested in trial NCT03143543?

The interventions under investigation include: Group A Lorcaserin (10mg) (DRUG), Group A2 Lorcaserin (20 mg) (DRUG), Group B Parallel Placebo (OTHER), Group B2 Parallel Placebo (OTHER).

Who is sponsoring clinical trial NCT03143543?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03143543's enrollment target sits among peer trials

171 324th of 2000 higher than 1,676 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02641145 · 171 participants · NA

    Molecular Imaging of Primary Amyloid Cardiomyopathy

  • NCT05541029 · 171 participants · NA

    Music Listening: A Mechanistic Trial

  • NCT05561127 · 171 participants · Phase 3

    Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

  • NCT05592938 · 171 participants · NA

    Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03143543, the US trial registry maintained by the National Library of Medicine. NCT03143543 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.